Drug intelligence / Profile preview

clevudine + peginterferon

Development stage
Unknown
Lead developer
Gilead Sciences
Modality
Recombinant Proteins and Enzymes, Small Molecules
Administration
Oral, Subcutaneous
01

Overview

Clevudine + peginterferon is a combination therapy investigated for the treatment of chronic hepatitis B virus (HBV) infection. Clevudine is a nucleoside analog antiviral that inhibits HBV DNA polymerase through non-competitive inhibition by its triphosphate form, interfering with viral replication[6]. Peginterferon (specifically peginterferon alfa-2a) is a recombinant interferon conjugated to polyethylene glycol to extend its half-life; it acts as an immunomodulator by binding to type 1 interferon receptors and inducing antiviral responses in host cells[1][4]. This combination aims to enhance antiviral efficacy against HBV by targeting the virus through two distinct mechanisms.

Brand names
Pegasys ProClick
Other names
clevudinepeginterferon alfa-2a
02

Targets

HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on clevudine + peginterferon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clevudine + peginterferon.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call